Although the TMEM154-RASGRF1 translocation is likely to be a rare occurrence (as has been the case in the past with other translocations), it is predicted that further study of its biology will yield important insights into retinoic acid signaling and resistance to retinoid-based therapy in AML. This evidence concerns the gene RASGRF1 and acute myeloid leukemia.